Christie Orschell

Permanent URI for this collection

https://hdl.handle.net/1805/14111

Side effects of cancer chemotherapy and radiotherapy include destruction of bone marrow stem and progenitor cells. These cells help the body fight against life-threatening infection and hemorrhage. Exposure from radiological terrorism or accidents also leads to severe bone marrow damage. There are many FDA-approved medications to help bone marrow recovery after cancer treatment, but currently only two approved medical countermeasures (MCM) for individuals exposed to lethal doses of radiation. These medications, Neupogen and Neulasta, are “repurposed” from the cancer field.

Dr. Christie Orschell’s laboratory developed mouse models of the Hematopoietic-Acute Radiation Syndrome (H-ARS) and the Delayed Effects of Acute Radiation Exposure (DEARE) for efficacy testing of MCM against radiation according to the FDA Animal Rule. Under the Animal Rule, which guides drug development when human efficacy studies are unethical or unfeasible, development of radiation MCMs must first use animal models. Her models contributed to the approval of Neupogen and Neulasta, and have been promoted by the NIH to undergo qualification as a “drug development tool” by the FDA, which would allow the model to be publicly available for use in drug development programs and included in FDA submissions without the need to reconfirm suitability of the model.

Dr. Orschell’s work to develop animal models for radiation drug discovery is another example of how IUPUI faculty are TRANSLATING RESEARCH INTO PRACTICE.

Browse

Browsing Christie Orschell by Subject "acute radiation exposure"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Delayed effects of acute radiation exposure on the cardiovascular system using a murine model of the hematopoietic acute radiation syndrome
    (Office of the Vice Chancellor for Research, 2016-04-08) Thungu, Beatrice; Ortiz, Miguel; Unthank, Joseph L.; Orschell, Christie M.; Miller, Steven J.
    Introduction. Exposure to high level radiation from accidents or belligerent activities results in acute and chronic organ damage. The hematopoietic system is the most sensitive organ to radiation damage (2-10 Gy) and results in the hematopoietic acute radiation syndrome (H-ARS). Survivors of H-ARS are plagued months to years later with delayed effects of acute radiation exposure (DEARE), characterized by chronic illnesses affecting multiple organ systems. Previous results using the murine H-ARS model showed numerous kidney and heart DEARErelated pathologies similar to humans, including tissue fibrosis and elevated blood urea nitrogen. The goal of this study was to utilize the murine H-ARS model to determine possible roles for abnormal iron metabolism, inflammation, oxidant stress, and senescence in the development of cardiac DEARE. Methods. Mice (C57BL/6; 12 week-old) received total body irradiation (TBI: ~8.5-8.7 Gy, 137Cs, LD50to LD70) and hearts were harvested at various times post-TBI from H-ARS survivors. Paraffin tissue sections were stained with hematoxylin/eosin or Perls Prussian Blue, or reacted with a macrophage-specific antibody (F4/80). Total RNA was purified from fresh tissue and changes in mRNA expression were assessed by real-time PCR for the senescence marker p16 and NADPH oxidase subunits Nox2, Nox4, or p47phox. Results/Significance. Compared to age-matched non-irradiated controls (NI), tissue iron deposits were increased in irradiated (IR) hearts at 4 months, and progressively declined with time post-TBI. Numbers of macrophages were greater in IR vs. NI sections at all time points and decreased with time post-TBI. Nox2 and Nox4 mRNA expression was increased at both 9 and 21 months post-TBI, but p47phox increased only at 21 months. Expression of p16 in IR heart was increased at 7, but not at 22 months post-TBI. Taken together, the results indicate abnormal iron metabolism, inflammation, oxidant stress, and early senescence may contribute to development of cardiac DEARE.